According to Bellerophon Therapeutics 's latest financial reports the company's total liabilities are HK$9.85 Million. A companyโs total liabilities is the sum of all current and non-current debts and obligations.
Year | Total liabilities | Change |
---|---|---|
2022-12-31 | HK$42.19 M | 2.97% |
2021-12-31 | HK$40.98 M | -55.91% |
2020-12-31 | HK$92.94 M | 25.4% |
2019-12-31 | HK$74.11 M | -34.74% |
2018-12-31 | HK$0.11 B | -63.11% |
2017-12-31 | HK$0.30 B | 239.03% |
2016-12-31 | HK$90.8 M | 45.12% |
2015-12-31 | HK$62.57 M | -22.83% |
2014-12-31 | HK$81.08 M | -46.02% |
2013-12-31 | HK$0.15 B | 33.98% |
2012-12-31 | HK$0.11 B |
Company | Total liabilities | differencediff. | Country |
---|---|---|---|
![]() Baxter BAX | HK$111.85 B | 1,134,454.14% | ๐บ๐ธ USA |
![]() Abeona Therapeutics
ABEO | HK$0.45 B | 4,515.29% | ๐บ๐ธ USA |
![]() Abbott Laboratories ABT | HK$254.20 B | 2,578,243.95% | ๐บ๐ธ USA |
![]() Lantheus Holdings LNTH | HK$6.99 B | 70,841.88% | ๐บ๐ธ USA |